News
-
May. 28, 2026EnPlusOne Biosciences Welcomes Biotech Veteran, Jim Weissman, to Board of Directors
-
May. 12, 2026
EnPlusOne Biosciences Highlights Significant Advancements to its ezRNA™ Enzymatic RNA Synthesis Platform and Introduces Novel Modifications for Next-Generation RNA Therapeutics
-
May. 06, 2026
CEO Clare Murray, Ph.D. Discusses EnPlusOne’s ezRNA Platform on Biotech TV
-
Oct. 21, 2025
Breakout Ventures 2025 Annual Meeting, Presentation by Clare Murray
-
May. 15, 2025
EnPlusOne Biosciences To Present New Data at TIDES USA
-
Apr. 25, 2025
EnPlusOne Biosciences Appoints Clare Murray, Ph.D. as CEO
-
Feb. 27, 2025EnPlusOne Raises $10m in Financing
-
Aug. 15, 2024EnPlusOne Biosciences to Collaborate with Wyss Institute on Up to $27 Million Agreement By ARPA-H to Develop Disease-Agnostic Immunotherapeutic RNA Platform
-
Aug. 13, 2024Nature Biotechnology publishes pivotal EnPlusOne paper on Template-Independent Enzymatic Synthesis of RNA Oligonucleotides
-
Jul. 09, 2024EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand
EnPlusOne, a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, revealed today that it had achieved the successful synthesis of the antisense strand of the commercially approved siRNA drug, Leqvio® (inclisiran), a treatment for hypercholesteremia (high-cholesterol). Licensed from Alnylam Pharmaceuticals, Inc. by Novartis, Leqvio® currently addresses a multi-million patient population.